GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00602498 | Cervix | CC | anatomical structure homeostasis | 63/2311 | 314/18723 | 6.03e-05 | 8.68e-04 | 63 |
GO:0044262 | Colorectum | AD | cellular carbohydrate metabolic process | 87/3918 | 283/18723 | 6.00e-05 | 1.01e-03 | 87 |
GO:0005996 | Colorectum | AD | monosaccharide metabolic process | 80/3918 | 257/18723 | 7.31e-05 | 1.17e-03 | 80 |
GO:0060249 | Colorectum | AD | anatomical structure homeostasis | 94/3918 | 314/18723 | 9.37e-05 | 1.42e-03 | 94 |
GO:00602491 | Colorectum | SER | anatomical structure homeostasis | 74/2897 | 314/18723 | 1.01e-04 | 2.13e-03 | 74 |
GO:00059961 | Colorectum | SER | monosaccharide metabolic process | 59/2897 | 257/18723 | 9.65e-04 | 1.15e-02 | 59 |
GO:00602492 | Colorectum | MSS | anatomical structure homeostasis | 84/3467 | 314/18723 | 1.87e-04 | 2.64e-03 | 84 |
GO:00059962 | Colorectum | MSS | monosaccharide metabolic process | 66/3467 | 257/18723 | 2.61e-03 | 2.06e-02 | 66 |
GO:00602493 | Colorectum | MSI-H | anatomical structure homeostasis | 38/1319 | 314/18723 | 7.73e-04 | 1.44e-02 | 38 |
GO:00442621 | Colorectum | FAP | cellular carbohydrate metabolic process | 66/2622 | 283/18723 | 1.53e-05 | 4.01e-04 | 66 |
GO:00059963 | Colorectum | FAP | monosaccharide metabolic process | 59/2622 | 257/18723 | 6.79e-05 | 1.28e-03 | 59 |
GO:00602494 | Colorectum | FAP | anatomical structure homeostasis | 69/2622 | 314/18723 | 7.51e-05 | 1.37e-03 | 69 |
GO:00602495 | Colorectum | CRC | anatomical structure homeostasis | 57/2078 | 314/18723 | 1.24e-04 | 2.41e-03 | 57 |
GO:00442622 | Colorectum | CRC | cellular carbohydrate metabolic process | 49/2078 | 283/18723 | 1.06e-03 | 1.24e-02 | 49 |
GO:00610417 | Liver | NAFLD | regulation of wound healing | 39/1882 | 134/18723 | 5.52e-10 | 1.28e-07 | 39 |
GO:00420607 | Liver | NAFLD | wound healing | 84/1882 | 422/18723 | 6.56e-10 | 1.37e-07 | 84 |
GO:0042730 | Liver | NAFLD | fibrinolysis | 15/1882 | 25/18723 | 1.26e-09 | 2.30e-07 | 15 |
GO:0030195 | Liver | NAFLD | negative regulation of blood coagulation | 21/1882 | 49/18723 | 2.42e-09 | 4.05e-07 | 21 |
GO:1900047 | Liver | NAFLD | negative regulation of hemostasis | 21/1882 | 50/18723 | 3.78e-09 | 5.40e-07 | 21 |
GO:0030193 | Liver | NAFLD | regulation of blood coagulation | 24/1882 | 66/18723 | 9.30e-09 | 1.26e-06 | 24 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0517114 | Liver | NAFLD | Coronavirus disease - COVID-19 | 111/1043 | 232/8465 | 1.01e-41 | 3.32e-39 | 2.67e-39 | 111 |
hsa04610 | Liver | NAFLD | Complement and coagulation cascades | 35/1043 | 86/8465 | 2.48e-11 | 2.04e-09 | 1.64e-09 | 35 |
hsa0517115 | Liver | NAFLD | Coronavirus disease - COVID-19 | 111/1043 | 232/8465 | 1.01e-41 | 3.32e-39 | 2.67e-39 | 111 |
hsa046101 | Liver | NAFLD | Complement and coagulation cascades | 35/1043 | 86/8465 | 2.48e-11 | 2.04e-09 | 1.64e-09 | 35 |
hsa0517122 | Liver | Cirrhotic | Coronavirus disease - COVID-19 | 136/2530 | 232/8465 | 3.28e-20 | 1.82e-18 | 1.12e-18 | 136 |
hsa046102 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
hsa0517132 | Liver | Cirrhotic | Coronavirus disease - COVID-19 | 136/2530 | 232/8465 | 3.28e-20 | 1.82e-18 | 1.12e-18 | 136 |
hsa046103 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
hsa0517142 | Liver | HCC | Coronavirus disease - COVID-19 | 167/4020 | 232/8465 | 1.50e-14 | 4.19e-13 | 2.33e-13 | 167 |
hsa046104 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
hsa046112 | Liver | HCC | Platelet activation | 71/4020 | 124/8465 | 1.77e-02 | 4.15e-02 | 2.31e-02 | 71 |
hsa0517152 | Liver | HCC | Coronavirus disease - COVID-19 | 167/4020 | 232/8465 | 1.50e-14 | 4.19e-13 | 2.33e-13 | 167 |
hsa046105 | Liver | HCC | Complement and coagulation cascades | 57/4020 | 86/8465 | 3.19e-04 | 1.45e-03 | 8.04e-04 | 57 |
hsa0461111 | Liver | HCC | Platelet activation | 71/4020 | 124/8465 | 1.77e-02 | 4.15e-02 | 2.31e-02 | 71 |
hsa0517162 | Liver | Cyst | Coronavirus disease - COVID-19 | 75/339 | 232/8465 | 2.97e-49 | 4.27e-47 | 3.53e-47 | 75 |
hsa0517172 | Liver | Cyst | Coronavirus disease - COVID-19 | 75/339 | 232/8465 | 2.97e-49 | 4.27e-47 | 3.53e-47 | 75 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FGG | SNV | Missense_Mutation | | c.1036N>C | p.Asp346His | p.D346H | P02679 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D1-A16J-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD |
FGG | SNV | Missense_Mutation | | c.953G>A | p.Gly318Asp | p.G318D | P02679 | protein_coding | deleterious(0.02) | probably_damaging(1) | TCGA-D1-A17Q-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
FGG | SNV | Missense_Mutation | novel | c.1175N>A | p.Gly392Asp | p.G392D | P02679 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-D1-A1O7-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
FGG | SNV | Missense_Mutation | novel | c.592N>A | p.Leu198Met | p.L198M | P02679 | protein_coding | tolerated(0.11) | possibly_damaging(0.836) | TCGA-DF-A2KV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
FGG | SNV | Missense_Mutation | | c.203C>A | p.Ser68Tyr | p.S68Y | P02679 | protein_coding | tolerated(0.41) | benign(0.001) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
FGG | SNV | Missense_Mutation | novel | c.670N>A | p.Leu224Ile | p.L224I | P02679 | protein_coding | tolerated(0.27) | benign(0.034) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
FGG | insertion | Frame_Shift_Ins | novel | c.1146dupA | p.Ala383SerfsTer5 | p.A383Sfs*5 | P02679 | protein_coding | | | TCGA-EO-A22U-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
FGG | SNV | Missense_Mutation | novel | c.1046A>T | p.Glu349Val | p.E349V | P02679 | protein_coding | deleterious(0.03) | benign(0.229) | TCGA-05-4405-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
FGG | SNV | Missense_Mutation | novel | c.68C>A | p.Thr23Lys | p.T23K | P02679 | protein_coding | deleterious(0.01) | benign(0.086) | TCGA-22-A5C4-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
FGG | SNV | Missense_Mutation | | c.501N>A | p.Asp167Glu | p.D167E | P02679 | protein_coding | tolerated(0.06) | probably_damaging(0.999) | TCGA-39-5019-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2266 | FGG | DRUGGABLE GENOME, FIBRINOGEN, EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE | | ALFIMEPRASE | ALFIMEPRASE | |
2266 | FGG | DRUGGABLE GENOME, FIBRINOGEN, EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE | | eptifibatide | EPTIFIBATIDE | 20938371 |
2266 | FGG | DRUGGABLE GENOME, FIBRINOGEN, EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE | inhibitor | CHEMBL1201505 | FIBRINOLYSIN, HUMAN | |
2266 | FGG | DRUGGABLE GENOME, FIBRINOGEN, EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE | | RECOMBINANT FACTOR IX FC FUSION PROTEIN | | |
2266 | FGG | DRUGGABLE GENOME, FIBRINOGEN, EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE | | tirofiban | TIROFIBAN | 20938371 |
2266 | FGG | DRUGGABLE GENOME, FIBRINOGEN, EXTERNAL SIDE OF PLASMA MEMBRANE, CELL SURFACE | | abciximab | ABCIXIMAB | 20938371 |